Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
November 4, 2024 / GLP-1 Drugs / Novo Nordisk Partnership / Obesity Treatment Innovation / Diabetes / Drug Delivery / Cardiometabolic Disease Therapies
Novo Nordisk and Ascendis Pharma are partnering to develop long-acting GLP-1 drugs for obesity, diabetes, and cardiovascular disease, leveraging Ascendis’ delivery technology to potentially improve treatment adherence with less frequent dosing.
Metabolic Syndrome and Obesity Drive Knee Osteoarthritis Progression
November 4, 2024 / Metabolic Syndrome Knee Osteoarthritis / Abdominal Obesity Osteoarthrisis
Metabolic syndrome, particularly abdominal obesity and high blood pressure, accelerates knee osteoarthritis progression. The association differs by sex, with MetS and triglycerides impacting chronic knee pain in men, while high blood pressure affects pain in women.
Study shows people who had bariatric surgery as teens have improved health outcomes
November 4, 2024 / Adolescent Bariatric Surgery / Teen Obesity Treatment Outcomes / Long-term Obesity Management / Type 2 Diabetes Remission
A 10-year study shows that bariatric surgery for teens with severe obesity leads to sustained BMI reduction and improvements in hypertension, type 2 diabetes, and other conditions, highlighting its effectiveness and safety as a long-term treatment option.
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug
November 4, 2024 / Viking Therapeutics / Oral Obesity Drug Trials / GLP-1 GIP Receptor Agonists / Weight Loss Medications / Obesity Treatment
Viking Therapeutics’ oral VK2735 showed promising weight loss results, achieving up to 6.8% reduction in Phase 1 trials with good tolerability. Analysts highlight its potential as a best-in-class oral obesity drug and a complementary maintenance option.
Dysregulated metabolic pathways in late pregnancy tied to higher type 2 diabetes incidence
November 4, 2024 / Gestational Diabetes Type 2 Risk / Late Preganancy Metabolic Pathways / Amino Acid Dysregulation Diabetes / Fatty Acid Metabolism / Insulin Sensitivity Postpartum
In women with gestational diabetes, dysregulated amino acid metabolism during late pregnancy correlates with higher type 2 diabetes risk, while certain fatty acid and lipid dysregulations appear protective, influencing insulin sensitivity and glucose control postpartum.
Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease
November 4, 2024 / Metabolic Symdrome / Steatotic Liver Disease Risks / MRI Fat Measurement Obesity / Metabolic Syndrome Predictors
MRI-measured perirenal fat thickness independently predicts metabolic syndrome in patients with steatotic liver disease, correlating significantly with waist circumference and hepatic fat. Higher perirenal fat levels are associated with increased risk of metabolic syndrome indicators like hypertension and diabetes.
Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes
November 4, 2024 / Cytoki Pharma / CK-0045 Phase 2 Trial / Obesity Treatment / Muscle-sparing Weight Loss / Metabolic Disease Innovation
Cytoki Pharma has dosed the first patient in a Phase 2 trial of CK-0045, an IL-22 analogue for obesity and type 2 diabetes. This novel treatment aims to promote muscle-sparing weight loss and metabolic benefits beyond body weight reduction.
Novo’s obesity blockbuster semaglutide before label extension
November 4, 2024 / Novo Nordisk / Semaglutide MASH Treatment / Liver Fibrosis Improvement / GLP-1 Obesity Drug Extension / Metabolic Liver Disease Therapy
Novo Nordisk’s semaglutide achieved significant liver fibrosis and steatohepatitis improvement in adults with MASH and moderate to advanced fibrosis in Phase III ESSENCE study, supporting potential FDA and EU filings in 2025 for expanded indications.
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis
November 4, 2024 / AIM-MASH AI Pathology Tool / MASH Clinical Trial Scoring / Metabolic Liver Disease AI
AIM-MASH, an AI-based pathology tool, demonstrated high reliability in assessing liver biopsies for MASH. It reduces reader variability in clinical trials, potentially streamlining MASH drug evaluations by providing consistent, standardized scoring for enrollment and endpoints.
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD
November 4, 2024 / Denifanstat Phase 3 Trials / MASLD MASH Treatment / Fatty Liver Disease Therapy / FDA Breakthrough Designation
Sagimet Biosciences plans two Phase 3 trials to test denifanstat, an oral FASN inhibitor, for MASLD and MASH, following FDA guidance. Denifanstat targets liver fat, inflammation, and fibrosis, aiming to slow disease progression in fatty liver disease.
Association between neutrophil-percentage-to-albumin ratio (NPAR) and metabolic syndrome risk: insights from a large US population-based study
November 4, 2024 / NPAR Metabolic Syndrome Risk / MetS Inflammation Biomarkers
A high Neutrophil-Percentage-to-Albumin Ratio (NPAR) correlates with increased metabolic syndrome (MetS) risk, with serum uric acid and TyG index partly mediating this relationship. This study suggests NPAR as a potential biomarker for MetS risk assessment.
Relationship between physical activity and abdominal obesity and metabolic markers in postmenopausal women
November 3, 2024 / Postmenopausal Obesity / Physical Activity Benefits / Metabolic Syndrome / Abdominal Fat Reduction
Physical activity, particularly moderate-to-vigorous, correlates with reduced abdominal obesity and improved metabolic markers in postmenopausal women, suggesting a protective effect against metabolic syndrome and cardiovascular disease through enhanced energy metabolism and decreased adiposity.
Sleep Experts Warn: Exposure to Night Light Increases Death Risk by 34%
November 3, 2024 / Night Light Exposure Health Risks / Cardiometabolic Disease / Bright Daylight Longevity Benefits
Bright nights and dim days disrupt circadian rhythms, elevating mortality risk by increasing susceptibility to cardiometabolic diseases. Consistent exposure to daytime light and minimizing nighttime light may promote health and longevity.
Insulin resistance caused by sympathetic nervous system over-activation, a paradigm-shifting study finds
November 2, 2024 / Sympathetic Nervous System Insulin / Obesity and SNS Overactivation / Insulin Resistance Mechanism / Type 2 Diabetes Prevention / Metabolic Health
A Rutgers study shows that overactivation of the sympathetic nervous system (SNS), triggered by overnutrition, drives insulin resistance, offering a new perspective on obesity-induced insulin resistance and potential avenues for type 2 diabetes prevention.
Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study
November 2, 2024 / MASH Diagnosis Noninvative / Liver Disease / Metabolic Liver Disease Obesity / Bariatric Surgery / MASH
A European multicenter study validated mid-infrared (MIR) spectroscopy as a noninvasive blood test for diagnosing MASH in women with severe obesity, showing high sensitivity and specificity. Further research is needed to confirm its effectiveness in men.
Anti-Obesity Drug Use Rises, While Weight Loss Surgeries Are Down 25%
November 1, 2024 / GLP-1 Obesity Treatment / Bariatric Surgery Decline / Anti-Obesity Drug Trends / Obesity Treatment Access
GLP-1 RA use for obesity more than doubled from 2022 to 2023, while bariatric surgeries declined by 25.6%. Researchers call for increased access to both pharmacologic and surgical treatments to optimize obesity care.
How does overeating lead to diabetes? A surge of neurotransmitters
October 31, 2024 / High-fat Diet Diabetes Link / Sympathetic Nervous System Insulin / Neurotransmitters and Obesity / Fatty Acid Relese in Diabetes
A high-fat diet may lead to diabetes through neurotransmitter surges, driven by the sympathetic nervous system, which accelerates fatty tissue breakdown and insulin resistance. This insight shifts focus from insulin malfunction to nervous system signaling.
Metabolic syndrome linked to dementia risk in Parkinson’s study
October 31, 2024 / Parkinson’s Dementia Metabolic Syndrome / Parkinson’s Disease Risk / Cognitive Decline and Metabolism / Metabolic Health
Metabolic syndrome significantly raises dementia risk in Parkinson’s patients, with higher blood sugar correlating to worse cognitive function. Managing metabolic syndrome may reduce cognitive decline, emphasizing a therapeutic focus on metabolic health in Parkinson’s.
What to know about obesity in Down syndrome
October 30, 2024 / Down Syndrome Obesity / Obesity Risk Factors / Hypothyroidism / Weight Loss / Obesity Management
People with Down syndrome have a higher risk of obesity due to factors like hypothyroidism, leptin resistance, and lower energy expenditure. Managing obesity involves dietary changes, increased physical activity, and addressing underlying health conditions.
SELECT ‘legitimized obesity medical therapy’ for treatment of cardiometabolic disease
October 4, 2024 / Semaglutide Cardiometabolic Benefits / SELECT Trial Results / Obesity Pharmacotherapy / Cardiovascular Risk Reduction / Weight Loss in CVD
The SELECT trial demonstrates that semaglutide significantly reduces cardiovascular events in patients with obesity and prior CVD. Its efficacy in weight reduction, glycemic control, and inflammatory marker improvement strengthens the role of obesity pharmacotherapy in cardiometabolic disease management.